Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revived TranS1 Rebuilds Exec Team With New Sales VP

This article was originally published in Clinica

Executive Summary

TranS1, which has emerged from the ashes after its previous incarnation Baxano filed for bankruptcy last year, has appointed John Miller Vice-President of Sales. Miller\, joins from Boston firm SpineFrontier but previously served a stint with Baxano before. He will oversee the commercialization of AxiaLIF, the axial lumbar interbody fusion system that allows less invasive restabilization of the spine. TranS1 was restructured under new ownership earlier this year; it had merged with Baxano in 2013 and the combined entity was renamed Baxano. However the company ran into financial trouble, and filed for bankruptcy in November last year. Aside from Miller, the other two members of TranS1’s new executive team have a legal background. President and CEO Jeffrey Schell is a patent attorney by training, and the Executive VP and General Counsel is said to “have a track record as a successful litigator”.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT102881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel